(Q38207142)

31 August 2017

title

Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs (English)

1 reference

31 August 2017

1 reference

Luca Semerano

1

1 reference

31 August 2017

Allan Thiolat

2

1 reference

31 August 2017

Emeline Minichiello

3

1 reference

31 August 2017

Gaëlle Clavel

4

1 reference

31 August 2017

Natacha Bessis

5

1 reference

31 August 2017

Marie-Christophe Boissier

6

1 reference

31 August 2017

language of work or name

English

0 references

publication date

26 April 2014

1 reference

Expert Opinion on Investigational Drugs

31 August 2017

number of pages

21

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

31 August 2017

volume

23

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

979-999

1 reference

Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Targeting lymphocyte activation to treat rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

The role of tocilizumab in the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

IL-6: from its discovery to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Interleukin 6: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

The regulation of TNF signalling: what a tangled web we weave

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

The problem of choice: current biologic agents and future prospects in RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Interleukin 6 and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Strategies and challenges for the next generation of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Cord blood-derived macrophage-lineage cells rapidly stimulate osteoblastic maturation in mesenchymal stem cells in a glycoprotein-130 dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

Do we need therapeutic trials comparing biotherapies to guide treatment selection in patients with rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.912276

10.1517/13543784.2014.912276

21 January 2018

Identifiers

DOI

1 reference

release_aem6vzw4wvbipk2oo2p23y64ui

31 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/aem6vzw4wvbipk2oo2p23y64ui

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference